Last reviewed · How we verify
NCT05715567
Re-EValuating the Inhibition of Stress Erosions (REVISE) - COVID-19 Cohort Study
trial testing Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800) in COVID-19 in 600 participants. Status unknown.
31 October 2023
Quick facts
| Lead sponsor | McMaster University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 1 December 2021 |
| Primary completion | 31 October 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- GastroIntestinal Bleeding — all drugs for GastroIntestinal Bleeding →
Sponsor
McMaster University
Who can join
18 and older, any sex, with COVID-19 or GastroIntestinal Bleeding. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Commonly employed medications used in critically ill patients requiring life support include proton pump inhibitors (PPIs). These medications are thought to prevent gastrointestinal (GI) bleeding from stress-induced ulceration. Despite their widespread use, they do hold some risks which include infection in the form of pneumonia and diarrheal illnesses such as Clostridioides difficile infection (C. difficile). Emerging high-quality studies suggest PPI usage does not influence susceptibility to COVID-19 infection, however some studies suggest PPI use leads to poor outcomes in this population, including prolonged time on life-support and death. While we can appreciate the negative effects of PPI may be magnified in the sickest of patients, namely hospitalized patients with COVID-19, the beneficial or potentially harmful role they play in this population remains unclear. We aim to build a clinical profile to further describe critically ill patients with COVID-19 in Ontario using the infrastructure of an ongoing multicenter clinical trial of acid suppression. We will identify characteristics that predict poor outcomes among sick COVID patients, examining the impact of PPIs on this population.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Protocol implementation during the COVID-19 pandemic: experiences from a randomized trial of stress ulcer prophylaxis.
Dennis B, Deane A, Lauzier F, Zytaruk N, et al · · 2024 · cited 3× · PMID 38704520 · DOI 10.1186/s12874-024-02233-2 -
Proton pump inhibitors in critically ill mechanically ventilated patients with COVID-19: protocol for a substudy of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial.
Dennis BB, Thabane L, Heels-Ansdell D, Dionne JC, et al · · 2023 · cited 2× · PMID 37644556 · DOI 10.1186/s13063-023-07589-2
Verify or expand the search:
- PubMed search for NCT05715567
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other McMaster University trials
Trials by the same sponsor.
- NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
- NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
- NCT07486505 — Mindfulness in Fracture Recovery and Reduction of Opioid Reliance: Evaluating the Feasibility of Implementing a Brief, M · NA · not yet recruiting
- NCT07408128 — Partner4Exercise Randomized Controlled Trial · Phase 2, PHASE3 · not yet recruiting
- NCT07459777 — Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anteri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05715567 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McMaster University
- Last refreshed: 8 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05715567.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing